Leo Pharmaceutical Products Ltd. A/s

Leo Pharmaceutical Products Ltd. A/s (lovens Kemiske Fabrik

Leo-pharma A/s

Leo Pharmaceutical Products, Ltd.

Leo Pharmaceutical Products Ltd. A/s (l.o Slashed.vens Kemiske Fabrik

Leo Pharmaceutical Products Ltd. A/s Kemiske Fabrik Produkionsaktiese

Kai Holst Hansen

Martin John Calverley

Lise Binderup

Ernst T Binderup

Claus Aage Svensgaard Bretting

Henrik Pedersen

Ernst Torndal Binderup

Compounds according to formula I in which formula R1 and R2, which may be the same or different, represent halogen, (C-C)hydrocarbyl, optionally substituted with one or two hydroxyl group or one or more fluorine atoms, or, together with the carbon atom to which they are both attached, R1 and R2 form a (C-C)carbocyclic ring, or one of R1 and R2 taken together with R3 forms a direct bond, such that a triple bond is constituted, or R1 and R2 represent both hydrogen; R3 when not forming a direct bond with one of R1 and R2 represents hydrogen or (C-C)hydrocarbyl; X represents (E)-ethylene, (Z)-ethylene, ethynylene, or a bond; Y and Z independently represent hydrogen or methyl; and prodrugs and stereo isomeric forms thereof are provided together with their use in therapy, and their use in the manufacture of medicaments.

Vitamin d analogues, compositions comprising said analogues and their use

Vitamin D analogues

The present invention relates to compounds of general formula (I) wherein R and R , which may be the same or different, represent (C -C )alkyl, and R represents hydrogen, halogen, (C -C )alkyl, or O&mdash;(C -C )alkyl, and in-vivo hydrolysable esters there with pharmaceutically acceptable acids. The present compounds are of value in the human and veterinary practice.

Vitamin D analogues and their pharmaceutical use

Vitamin D analogues having a halogen-or azido- substituted side chain

##STR1## The present invention relates to compounds of formula (I), in which formula R stands for an alkyl group containing from 7 to 12 carbon atoms optionally substituted with a hydroxy group; and derivatives of the compounds of formula (I) in which one or more hydroxy groups have been transformed into --O-acyl or --O-glycosyl or phosphate ester groups, such masked groups being hydrolyzable in vivo, in pure form or in mixtures. The present compounds find use in both the human and veterinary practice in the treatment and prophylaxis of autoimmune diseases, including diabetes mellitus, hypertension, inflammatory diseases such as rheumatoid arthritis and asthma as well as diseases characterized by abnormal cell differentiation and/or cell proliferation, and/or imbalance in the immune system.

The present invention relates to hitherto unknown esters of the below formula I, to salts of the esters of formula I with pharmaceutically acceptable acids, to methods for producing said new compounds, to pharmaceutical compositions containing said new compounds, and to methods of treating patients suffering from infectious diseases using said new compounds. The compounds of the invention, which are valuable in the human and veterinary practice, have the formula I ##STR1## in which R.sub.1 and R.sub.2 represent the same or different substituents, and each represents hydrogen or lower alkyl;

Bis-penicillanoyloxy-alkanes

Growing community of inventors

Herlev, Denmark

Kai Holst Hansen